Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13D/A for Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value (CBIO).
- Disclosed ownership: 19%.
- Date of event: 04 Dec 2025.
Fairmount Funds Management LLC - 04 Dec 2025 SCHEDULE 13D/A Report for Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value (CBIO)
- Filing Manager
- Fairmount Funds Management LLC
- Reporting Manager
- Fairmount Funds Management LLC
- Symbol
- CBIO
- Shares outstanding
- 30,455,920 shares
- Disclosed Ownership
- 5,643,482 shares
- Ownership
- 19%
- Form type
- SCHEDULE 13D/A
- Filing time
- 08 Dec 2025, 16:30:27 UTC
- Date of event
- 04 Dec 2025
- Previous filing
- 23 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 19% ownership in Crescent Biopharma, Inc. Ordinary Shares, $0.001 par value (CBIO) on 04 Dec 2025."
What Changed
- Previous schedule filing date: 23 Jun 2025.
- Current filing was accepted on 08 Dec 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 19% | 5,643,482 | 0 | 5,643,482 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001802528 |
| Fairmount Healthcare Fund II L.P. | 19% | 5,643,482 | 0 | 5,643,482 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001769651 |
| Peter Evan Harwin | 19% | 5,643,482 | 0 | 5,643,482 | /s/ Peter Evan Harwin | Peter Evan Harwin | 0001663607 |
| Tomas Kiselak | 19% | 5,643,482 | 0 | 5,643,482 | /s/ Tomas Kiselak | Tomas Kiselak | 0001830177 |